ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

DH Peng, ST Kundu, JJ Fradette, L Diao… - Science translational …, 2019 - science.org
Science translational medicine, 2019science.org
Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors have failed to show clinical
benefit in Kirsten rat sarcoma (KRAS) mutant lung cancer due to various resistance
mechanisms. To identify differential therapeutic sensitivities between epithelial and
mesenchymal lung tumors, we performed in vivo small hairpin RNA screens, proteomic
profiling, and analysis of patient tumor datasets, which revealed an inverse correlation
between mitogen-activated protein kinase (MAPK) signaling dependency and a zinc finger E …
Mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors have failed to show clinical benefit in Kirsten rat sarcoma (KRAS) mutant lung cancer due to various resistance mechanisms. To identify differential therapeutic sensitivities between epithelial and mesenchymal lung tumors, we performed in vivo small hairpin RNA screens, proteomic profiling, and analysis of patient tumor datasets, which revealed an inverse correlation between mitogen-activated protein kinase (MAPK) signaling dependency and a zinc finger E-box binding homeobox 1 (ZEB1)–regulated epithelial-to-mesenchymal transition. Mechanistic studies determined that MAPK signaling dependency in epithelial lung cancer cells is due to the scaffold protein interleukin-17 receptor D (IL17RD), which is directly repressed by ZEB1. Lung tumors in multiple Kras mutant murine models with increased ZEB1 displayed low IL17RD expression, accompanied by MAPK-independent tumor growth and therapeutic resistance to MEK inhibition. Suppression of ZEB1 function with miR-200 expression or the histone deacetylase inhibitor mocetinostat sensitized resistant cancer cells to MEK inhibition and markedly reduced in vivo tumor growth, showing a promising combinatorial treatment strategy for KRAS mutant cancers. In human lung tumor samples, high ZEB1 and low IL17RD expression correlated with low MAPK signaling, presenting potential markers that predict patient response to MEK inhibitors.
AAAS